Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics (NASDAQ: CTMX) has announced its 2025 strategic pipeline priorities, focusing primarily on CX-2051, their lead wholly-owned EpCAM PROBODY ADC program for advanced metastatic colorectal cancer. Initial Phase 1a clinical data is expected in H1 2025.

The company is implementing significant organizational changes, including a 40% reduction in headcount, primarily affecting non-partnered early research and administrative functions. These changes, along with focused clinical development priorities, are expected to extend their cash runway into Q2 2026. As of Q3 2024, the company had $117.6 million in cash and investments.

Three main clinical programs are in progress: CX-2051 (currently in sixth dose escalation cohort), CX-904 (enrolled over 70 patients), and CX-801 (Phase 1 dose escalation in metastatic melanoma). The company maintains research collaborations with Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron.

CytomX Therapeutics (CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Sean McCarthy, CEO and chairman, will engage in a fireside chat on December 4, 2024, at 8:00 a.m. ET. The presentation will be accessible via live webcast on CytomX's website. The company's management team will also be available for individual meetings with registered conference investors.

CytomX Therapeutics reported Q3 2024 financial results and pipeline updates. Revenue increased to $33.4 million from $26.4 million year-over-year. Cash position stood at $117.6 million as of September 30, 2024. The company's clinical pipeline progresses with three key programs: CX-904 (EGFR-CD3 T-cell engager) advancing in Phase 1a, CX-2051 (EpCAM ADC) in fifth dose escalation cohort for colorectal cancer, and CX-801 (interferon alpha-2b) initiating Phase 1 trials. Initial data for CX-2051 and CX-801 are expected in first half and second half of 2025, respectively.

CytomX Therapeutics (CTMX) has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. Investors can access the webcast through CytomX's investor relations website, and an archived version will be available afterward.

CytomX Therapeutics (Nasdaq: CTMX) has announced the dosing of the first patient with CX-801 in a Phase 1 study for solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine designed to target both immune-oncology sensitive and insensitive tumors. The study (NCT06462794) will evaluate CX-801 as monotherapy and in combination with Merck's KEYTRUDA® (pembrolizumab).

The trial will focus on patients with advanced melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma. CytomX aims to leverage its conditional activation platform to enhance interferon's therapeutic index, potentially making it a key component in immuno-oncology combination therapies.

CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in two upcoming investor conferences in September 2024:

1. H.C. Wainwright 26th Annual Global Investment Conference: Scheduled for September 11, 2024, in New York, NY. CytomX will give a formal presentation at 12:30 p.m. ET.

2. 2024 Cantor Global Healthcare Conference: Set for September 19, 2024, also in New York, NY. The company will participate in a fireside chat at 9:45 a.m. ET.

Live webcasts of both events will be available on CytomX's website. The company's management will also be available for one-on-one meetings with registered conference attendees.

CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, focused on PDAC, NSCLC, and HNSCC, with a program update expected by end of 2024.

2. CX-2051 (EpCAM targeting PROBODY® ADC) Phase 1 study is enrolling its third cohort, with initial data anticipated in H1 2025.

3. CX-801 (interferon alpha-2b PROBODY® cytokine) Phase 1 study has its first clinical site active, with initial data expected in H2 2025.

4. Q2 2024 financial results: Revenue of $25.1 million, cash position of $137.2 million as of June 30, 2024.

5. Chris Ogden promoted to Chief Financial Officer.

CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, has announced it will report second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following the announcement. Investors can access the live webcast from CytomX's website and register for the conference call. Participants are advised to register at least 10 minutes before joining. An archived replay of the webcast will be available on the company's website for those unable to attend the live event.

CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024, at 2:00 p.m. ET. The event will be webcast live on CytomX’s website, where a recording will also be available. Management will be available for one-on-one meetings with registered investors during the conference.